We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

85 hedge funds and large institutions have $393M invested in Krystal Biotech in 2019 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 5

80% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 20

12% more funds holding

Funds holding: 76 → 85 (+9)

6.99% more ownership

Funds ownership: 58.01% → 65% (+7%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1% less capital invested

Capital invested by funds: $397M → $393M (-$4.87M)

Holders
85
Holders Change
+9
Holders Change %
+11.84%
% of All Funds
1.86%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
14
Increased
36
Reduced
20
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$13.8M
2
PAMU
Pictet Asset Management (UK)
United Kingdom
+$9.95M
3
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$9.73M
4
VOYA Investment Management
VOYA Investment Management
Georgia
+$8.9M
5
BlackRock
BlackRock
New York
+$6.71M

Top Sellers

Rank Fund Capital Flow
1
AG
Artal Group
Luxembourg
-$6.71M
2
Millennium Management
Millennium Management
New York
-$4.74M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.09M
4
O
OrbiMed
New York
-$1.79M
5
MIM
Monashee Investment Management
Massachusetts
-$1.41M
Name Holding Trade Value Shares
Change 		Change in
Stake
SST
26
S Squared Technology
New York
$2.35M – – –
Charles Schwab
27
Charles Schwab
California
$2.29M +$2.02M +45,189 +217%
William Blair & Company
28
William Blair & Company
Illinois
$2.03M +$1.75M +39,225 +204%
ACM
29
Atika Capital Management
New York
$2.03M +$2.61M +58,319 New
Invesco
30
Invesco
Georgia
$1.64M +$2.11M +47,210 New
CIP
31
Chartwell Investment Partners
Pennsylvania
$1.57M +$2.02M +45,282 New
EGI
32
EAM Global Investors
California
$1.44M +$366K +8,192 +25%
N
33
Nuveen
North Carolina
$1.41M +$244K +5,450 +15%
Neuberger Berman Group
34
Neuberger Berman Group
New York
$1.41M +$1.11M +24,800 +157%
AA
35
ALPS Advisors
Colorado
$1.2M +$190K +4,260 +14%
UBS Group
36
UBS Group
Switzerland
$1.13M +$1.42M +31,843 +4,392%
Squarepoint
37
Squarepoint
New York
$1.11M -$336K -7,519 -19%
ACH
38
ArrowMark Colorado Holdings
Colorado
$1.06M – – –
GECH
39
Garnet Equity Capital Holdings
New York
$972K -$760K -17,000 -38%
Rafferty Asset Management
40
Rafferty Asset Management
New York
$925K +$1.19M +26,632 New
PPA
41
Parametric Portfolio Associates
Washington
$893K -$207K -4,621 -15%
Allianz Asset Management
42
Allianz Asset Management
Germany
$891K +$4.25K +95 +0.4%
TD Asset Management
43
TD Asset Management
Ontario, Canada
$884K +$241K +5,400 +27%
Swiss National Bank
44
Swiss National Bank
Switzerland
$712K – – –
Wells Fargo
45
Wells Fargo
California
$575K +$317K +7,102 +75%
California State Teachers Retirement System (CalSTRS)
46
California State Teachers Retirement System (CalSTRS)
California
$568K +$128K +2,866 +21%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$521K – – –
Dimensional Fund Advisors
48
Dimensional Fund Advisors
Texas
$496K +$638K +14,270 New
Millennium Management
49
Millennium Management
New York
$484K -$4.74M -105,975 -88%
Citigroup
50
Citigroup
New York
$481K +$509K +11,377 +463%
1
2
3 4

KRYS Hedge Fund Activity: Q3 2019 in Review

85 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q3 2019, worth a combined $393M — down 1.2% from $397M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new KRYS positions and 5 closed out — a net gain of 9 holders — while 36 added to existing stakes and 20 trimmed.

The largest buyer was State Street, adding an estimated $13.8M. The largest seller was Artal Group, cutting an estimated $6.71M.

  • 85 institutional investors held Krystal Biotech (KRYS) as of Q3 2019, up from 76 in Q2 2019.
  • Funds reported $393M of Krystal Biotech stock for Q3 2019, down 1.2% quarter-over-quarter.
  • 14 funds opened new Krystal Biotech positions in Q3 2019 and 5 closed out, a net change of +9 holders.
  • The largest Krystal Biotech buyer in Q3 2019 was State Street, an estimated $13.8M added.
  • The largest Krystal Biotech seller in Q3 2019 was Artal Group, an estimated $6.71M sold.

Based on aggregated 13F filings for Q3 2019.